EDIT
Editas Medicine, Inc.
Price Chart
Latest Quote
$2.69
+0.14 (+5.49%)
Current Price
| Previous Close | $2.55 |
| Open | $2.65 |
| Day High | $2.71 |
| Day Low | $2.56 |
| Volume | 3,286,390 |
Stock Information
| Shares Outstanding | 153.46M |
| Total Debt | $17.30M |
| Cash Equivalents | $123.65M |
| Revenue | $38.69M |
| Net Income | $-108.95M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $412.81M |
| EPS (TTM) | $-1.14 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $157.02M |
| Sales | $38.69M |
| Income | $-108.95M |
| Book/sh | $0.04 |
| Cash/sh | $0.81 |
| Employees | 87 |
Financial Ratios
| Quick Ratio | 3.17 |
| Current Ratio | 3.22 |
| Debt/Eq | 392.40 |
Returns & Margins
| ROA | -26.95% |
| ROE | -326.07% |
| Gross Margin | -109.24% |
| Operating Margin | -883.19% |
| Profit Margin | -281.59% |
Ownership
| Insider Ownership | 0.17% |
| Institutional Ownership | 49.26% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -2.87 |
| P/S | 10.67 |
| P/B | 59.78 |
Analyst Data
| Recommendation | none |
| Target Price | $5.78 |
Technical Indicators
| SMA20 | $2.82 |
| SMA50 | $2.95 |
| SMA200 | $2.66 |
| RSI | 30.56 |
| ATR | 0.2500 |
| Shares Float | 79.28M |
| Short Float | 9.83% |
| Short Ratio | 5.96 |
| Volatility | 2.10 |
| Rel Volume | 0.90 |
Performance History
| Week | +10.25% |
| Month | +9.35% |
| Quarter | +14.47% |
| 6 Months | +7.17% |
| YTD | +31.22% |
| Year | +25.70% |
| 3 Years | -76.55% |
| 5 Years | -92.81% |
| 10 Years | -90.94% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $2.69 | 3,286,400 |
| 2026-06-17 | $2.55 | 3,230,500 |
| 2026-06-16 | $2.36 | 2,258,700 |
| 2026-06-15 | $2.46 | 2,466,300 |
| 2026-06-12 | $2.50 | 1,907,200 |
| 2026-06-11 | $2.44 | 2,235,600 |
| 2026-06-10 | $2.48 | 1,486,000 |
| 2026-06-09 | $2.65 | 1,877,600 |
| 2026-06-08 | $2.64 | 1,477,600 |
| 2026-06-05 | $2.71 | 2,366,200 |
| 2026-06-04 | $2.99 | 2,512,800 |
| 2026-06-03 | $2.78 | 3,205,700 |
| 2026-06-02 | $2.82 | 3,919,100 |
| 2026-06-01 | $3.34 | 3,101,700 |
| 2026-05-29 | $3.46 | 3,910,800 |
| 2026-05-28 | $3.43 | 4,965,100 |
| 2026-05-27 | $3.57 | 16,930,100 |
| 2026-05-26 | $3.08 | 9,667,400 |
| 2026-05-22 | $2.76 | 1,021,300 |
| 2026-05-21 | $2.67 | 976,900 |
| 2026-05-20 | $2.60 | 1,373,600 |
| 2026-05-19 | $2.46 | 998,400 |
About Editas Medicine, Inc.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
đ° Latest News
Why Is Editas (EDIT) Down 12.4% Since Last Earnings Report?
Zacks âĸ 2026-06-04T15:30:13Z
CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?
Motley Fool âĸ 2026-05-31T16:31:48Z
Some Analysts Just Cut Their Editas Medicine, Inc. (NASDAQ:EDIT) Estimates
Simply Wall St. âĸ 2026-05-11T13:35:29Z
EDIT's Q1 Loss Narrower Than Expected, Pipeline in Focus
Zacks âĸ 2026-05-06T15:57:00Z
Company News for May 6, 2026
Zacks âĸ 2026-05-06T13:39:00Z
Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates
Zacks âĸ 2026-05-05T12:25:04Z
Why Is Black Diamond (BDTX) Up 19.3% Since Last Earnings Report?
Zacks âĸ 2026-04-15T15:30:02Z
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Zacks âĸ 2026-04-13T13:00:04Z
Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue?
Zacks âĸ 2026-04-08T15:30:02Z
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Zacks âĸ 2026-04-07T13:00:04Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $40,520,000 | $32,314,000 | $78,123,000 | $19,712,000 |
| Operating Revenue | $40,520,000 | $32,314,000 | $78,123,000 | $19,712,000 |
| Expenses | ||||
| Interest Expense | $6,171,000 | $2,190,000 | - | - |
| Total Expenses | $139,856,000 | $271,234,000 | $247,304,000 | $245,662,000 |
| Other Income Expense | $-62,863,000 | $-12,235,000 | $-1,604,000 | $1,293,000 |
| Other Non Operating Income Expenses | $-2,189,000 | $-3,000 | $-1,604,000 | $1,293,000 |
| Net Non Operating Interest Income Expense | $2,139,000 | $14,062,000 | $17,566,000 | $5,518,000 |
| Interest Expense Non Operating | $6,171,000 | $2,190,000 | - | - |
| Operating Expense | $139,856,000 | $271,234,000 | $247,304,000 | $245,662,000 |
| General And Administrative Expense | $49,903,000 | $71,987,000 | $69,653,000 | $70,704,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-160,060,000 | $-237,093,000 | $-153,219,000 | $-220,432,000 |
| Net Interest Income | $2,139,000 | $14,062,000 | $17,566,000 | $5,518,000 |
| Interest Income | $8,310,000 | $16,252,000 | $17,566,000 | $5,518,000 |
| Normalized Income | $-99,386,000 | $-224,861,000 | $-153,219,000 | $-220,432,000 |
| Net Income From Continuing And Discontinued Operation | $-160,060,000 | $-237,093,000 | $-153,219,000 | $-220,432,000 |
| Total Operating Income As Reported | $-160,010,000 | $-251,152,000 | $-169,181,000 | $-225,950,000 |
| Net Income Common Stockholders | $-160,060,000 | $-237,093,000 | $-153,219,000 | $-220,432,000 |
| Net Income | $-160,060,000 | $-237,093,000 | $-153,219,000 | $-220,432,000 |
| Net Income Including Noncontrolling Interests | $-160,060,000 | $-237,093,000 | $-153,219,000 | $-220,432,000 |
| Net Income Continuous Operations | $-160,060,000 | $-237,093,000 | $-153,219,000 | $-220,432,000 |
| Pretax Income | $-160,060,000 | $-237,093,000 | $-153,219,000 | $-220,432,000 |
| Special Income Charges | $-60,674,000 | $-12,232,000 | $0 | $0 |
| Interest Income Non Operating | $8,310,000 | $16,252,000 | $17,566,000 | $5,518,000 |
| Operating Income | $-99,336,000 | $-238,920,000 | $-169,181,000 | $-225,950,000 |
| Per Share | ||||
| Diluted EPS | $-1.80 | $-2.88 | $-2.02 | $-3.21 |
| Basic EPS | $-1.80 | $-2.88 | $-2.02 | $-3.21 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-87,938,000 | $-216,862,000 | $-163,117,000 | $-219,613,000 |
| Total Unusual Items | $-60,674,000 | $-12,232,000 | $0 | $0 |
| Total Unusual Items Excluding Goodwill | $-60,674,000 | $-12,232,000 | $0 | $0 |
| Reconciled Depreciation | $5,277,000 | $5,809,000 | $6,064,000 | $6,337,000 |
| EBITDA (Bullshit earnings) | $-148,612,000 | $-229,094,000 | $-163,117,000 | $-219,613,000 |
| EBIT | $-153,889,000 | $-234,903,000 | $-169,181,000 | $-225,950,000 |
| Diluted Average Shares | $88,745,908 | $82,338,220 | $75,965,633 | $68,664,822 |
| Basic Average Shares | $88,745,908 | $82,338,220 | $75,965,633 | $68,664,822 |
| Diluted NI Availto Com Stockholders | $-160,060,000 | $-237,093,000 | $-153,219,000 | $-220,432,000 |
| Restructuring And Mergern Acquisition | $60,674,000 | $12,232,000 | $0 | $0 |
| Research And Development | $89,953,000 | $199,247,000 | $177,651,000 | $174,958,000 |
| Selling General And Administration | $49,903,000 | $71,987,000 | $69,653,000 | $70,704,000 |
| Other Gand A | $30,660,000 | $38,446,000 | $42,728,000 | $70,704,000 |
| Salaries And Wages | $19,243,000 | $33,541,000 | $26,925,000 | $34,190,000 |
Fetched: 2026-06-20
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $27,288,000 | $134,274,000 | $349,097,000 | $360,680,000 |
| Total Assets | $186,534,000 | $341,589,000 | $499,153,000 | $514,321,000 |
| Total Non Current Assets | $22,639,000 | $52,274,000 | $158,324,000 | $157,567,000 |
| Other Non Current Assets | $2,976,000 | $5,223,000 | $8,588,000 | $5,253,000 |
| Current Assets | $163,895,000 | $289,315,000 | $340,829,000 | $356,754,000 |
| Other Current Assets | $2,074,000 | $3,136,000 | $7,531,000 | $7,335,000 |
| Receivables | $15,176,000 | $16,266,000 | $10,187,000 | $5,145,000 |
| Accounts Receivable | $15,176,000 | $16,266,000 | $10,187,000 | $5,145,000 |
| Cash Cash Equivalents And Short Term Investments | $146,645,000 | $269,913,000 | $323,111,000 | $344,274,000 |
| Cash And Cash Equivalents | $146,645,000 | $131,541,000 | $123,652,000 | $141,522,000 |
| Cash Equivalents | $146,645,000 | $131,541,000 | $123,652,000 | $141,522,000 |
| Investmentin Financial Assets | - | $0 | $104,024,000 | $93,097,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $18,102,000 | $35,032,000 | $36,536,000 | $43,946,000 |
| Long Term Debt And Capital Lease Obligation | $12,071,000 | $20,380,000 | $24,372,000 | $32,864,000 |
| Current Debt And Capital Lease Obligation | $6,031,000 | $14,652,000 | $12,164,000 | $11,082,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $159,246,000 | $207,315,000 | $150,056,000 | $153,641,000 |
| Total Non Current Liabilities Net Minority Interest | $113,000,000 | $130,090,000 | $86,839,000 | $93,531,000 |
| Other Non Current Liabilities | $2,815,000 | $3,072,000 | $1,800,000 | - |
| Non Current Deferred Liabilities | $98,114,000 | $106,638,000 | $60,667,000 | $60,667,000 |
| Current Liabilities | $46,246,000 | $77,225,000 | $63,217,000 | $60,110,000 |
| Current Deferred Liabilities | $5,000,000 | $11,221,000 | $8,221,000 | $8,221,000 |
| Payables And Accrued Expenses | $28,440,000 | $29,361,000 | $31,552,000 | $30,667,000 |
| Payables | $2,605,000 | $5,493,000 | $8,269,000 | $9,511,000 |
| Accounts Payable | $2,605,000 | $5,493,000 | $8,269,000 | $9,511,000 |
| Equity | ||||
| Common Stock Equity | $27,288,000 | $134,274,000 | $349,097,000 | $360,680,000 |
| Total Equity Gross Minority Interest | $27,288,000 | $134,274,000 | $349,097,000 | $360,680,000 |
| Stockholders Equity | $27,288,000 | $134,274,000 | $349,097,000 | $360,680,000 |
| Gains Losses Not Affecting Retained Earnings | $0 | $268,000 | $198,000 | $-3,601,000 |
| Retained Earnings | $-1,628,503,000 | $-1,468,443,000 | $-1,231,350,000 | $-1,078,131,000 |
| Other Equity Adjustments | - | $268,000 | $198,000 | $-3,601,000 |
| Other | ||||
| Ordinary Shares Number | $97,866,996 | $82,734,696 | $81,767,263 | $68,847,382 |
| Share Issued | $97,866,996 | $82,734,696 | $81,767,263 | $68,847,382 |
| Tangible Book Value | $27,288,000 | $134,274,000 | $349,097,000 | $360,680,000 |
| Invested Capital | $27,288,000 | $134,274,000 | $349,097,000 | $360,680,000 |
| Working Capital | $117,649,000 | $212,090,000 | $277,612,000 | $296,644,000 |
| Capital Lease Obligations | $18,102,000 | $35,032,000 | $36,536,000 | $43,946,000 |
| Total Capitalization | $27,288,000 | $134,274,000 | $349,097,000 | $360,680,000 |
| Additional Paid In Capital | $1,655,781,000 | $1,602,441,000 | $1,580,241,000 | $1,442,405,000 |
| Capital Stock | $10,000 | $8,000 | $8,000 | $7,000 |
| Common Stock | $10,000 | $8,000 | $8,000 | $7,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $98,114,000 | $106,638,000 | $60,667,000 | $60,667,000 |
| Long Term Capital Lease Obligation | $12,071,000 | $20,380,000 | $24,372,000 | $32,864,000 |
| Current Deferred Revenue | $5,000,000 | $11,221,000 | $8,221,000 | $8,221,000 |
| Current Capital Lease Obligation | $6,031,000 | $14,652,000 | $12,164,000 | $11,082,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $6,775,000 | $21,991,000 | $11,280,000 | $10,140,000 |
| Current Accrued Expenses | $25,835,000 | $23,868,000 | $23,283,000 | $21,156,000 |
| Net PPE | $19,663,000 | $47,051,000 | $45,712,000 | $59,217,000 |
| Accumulated Depreciation | $-28,353,000 | $-31,648,000 | $-26,260,000 | $-21,526,000 |
| Gross PPE | $48,016,000 | $78,699,000 | $71,972,000 | $80,743,000 |
| Leases | $8,403,000 | $11,749,000 | $9,648,000 | $9,761,000 |
| Construction In Progress | $0 | $827,000 | $2,060,000 | $1,573,000 |
| Other Properties | $37,679,000 | $61,682,000 | $58,723,000 | $68,055,000 |
| Machinery Furniture Equipment | $1,934,000 | $4,441,000 | $1,541,000 | $1,354,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $0 | $138,372,000 | $199,459,000 | $202,752,000 |
| Investments And Advances | - | $0 | $104,024,000 | $93,097,000 |
| Treasury Shares Number | - | - | $0 | - |
| Available For Sale Securities | - | - | $104,024,000 | $93,097,000 |
Fetched: 2026-06-20
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-165,848,000 | $-219,110,000 | $-136,897,000 | $-181,467,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-165,241,000 | $-210,284,000 | $-132,178,000 | $-177,349,000 |
| Cash Flow From Continuing Operating Activities | $-165,241,000 | $-210,284,000 | $-132,178,000 | $-177,349,000 |
| Operating Gains Losses | $2,193,000 | $149,000 | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-607,000 | $-8,826,000 | $-4,719,000 | $-4,118,000 |
| Investing Cash Flow | $138,668,000 | $162,146,000 | $-3,731,000 | $114,068,000 |
| Cash Flow From Continuing Investing Activities | $138,668,000 | $162,146,000 | $-3,731,000 | $114,068,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $42,848,000 | $0 | $117,079,000 | $0 |
| Financing Cash Flow | $40,470,000 | $56,027,000 | $118,039,000 | $1,284,000 |
| Cash Flow From Continuing Financing Activities | $40,470,000 | $56,027,000 | $118,039,000 | $1,284,000 |
| Net Other Financing Charges | $-2,872,000 | $55,244,000 | - | - |
| Net Common Stock Issuance | $42,848,000 | $0 | $117,079,000 | $0 |
| Common Stock Issuance | $42,848,000 | $0 | $117,079,000 | $0 |
| Other | ||||
| End Cash Position | $149,315,000 | $135,418,000 | $127,529,000 | $145,399,000 |
| Beginning Cash Position | $135,418,000 | $127,529,000 | $145,399,000 | $207,396,000 |
| Changes In Cash | $13,897,000 | $7,889,000 | $-17,870,000 | $-61,997,000 |
| Proceeds From Stock Option Exercised | $494,000 | $783,000 | $960,000 | $1,284,000 |
| Net Investment Purchase And Sale | $139,006,000 | $170,972,000 | $988,000 | $118,168,000 |
| Sale Of Investment | $139,006,000 | $257,189,000 | $259,505,000 | $433,354,000 |
| Purchase Of Investment | $0 | $-86,217,000 | $-258,517,000 | $-315,186,000 |
| Net PPE Purchase And Sale | $-338,000 | $-8,826,000 | $-4,719,000 | $-4,100,000 |
| Sale Of PPE | $269,000 | $0 | $0 | $18,000 |
| Purchase Of PPE | $-607,000 | $-8,826,000 | $-4,719,000 | $-4,118,000 |
| Change In Working Capital | $-31,229,000 | $3,450,000 | $-1,594,000 | $8,176,000 |
| Change In Other Working Capital | $-18,044,000 | $-8,463,000 | - | $-3,333,000 |
| Change In Other Current Liabilities | $-11,889,000 | $-233,000 | $-5,610,000 | $17,568,000 |
| Change In Other Current Assets | $12,624,000 | $4,492,000 | $6,633,000 | $-15,917,000 |
| Change In Payables And Accrued Expense | $-16,072,000 | $9,337,000 | $2,622,000 | $14,873,000 |
| Change In Accrued Expense | $-13,184,000 | $11,623,000 | $4,114,000 | $10,505,000 |
| Change In Payable | $-2,888,000 | $-2,286,000 | $-1,492,000 | $4,368,000 |
| Change In Account Payable | $-2,888,000 | $-2,286,000 | $-1,492,000 | $4,368,000 |
| Change In Prepaid Assets | $1,062,000 | $4,396,000 | $-197,000 | $-137,000 |
| Change In Receivables | $1,090,000 | $-6,079,000 | $-5,042,000 | $-4,878,000 |
| Changes In Account Receivables | $1,090,000 | $-6,079,000 | $-5,042,000 | $-4,878,000 |
| Other Non Cash Items | $5,722,000 | $1,775,000 | $1,596,000 | $-724,000 |
| Stock Based Compensation | $10,000,000 | $21,417,000 | $19,798,000 | $29,294,000 |
| Asset Impairment Charge | $3,758,000 | $0 | - | - |
| Amortization Of Securities | $-902,000 | $-5,791,000 | $-4,823,000 | $-724,000 |
| Depreciation Amortization Depletion | $5,277,000 | $5,809,000 | $6,064,000 | $6,337,000 |
| Depreciation And Amortization | $5,277,000 | $5,809,000 | $6,064,000 | $6,337,000 |
| Depreciation | $5,277,000 | $5,809,000 | $6,064,000 | $6,337,000 |
| Gain Loss On Sale Of PPE | $2,193,000 | $149,000 | $0 | $0 |
| Net Income From Continuing Operations | $-160,060,000 | $-237,093,000 | $-153,219,000 | $-220,432,000 |
| Unrealized Gain Loss On Investment Securities | - | - | - | $0 |
Fetched: 2026-06-20